Microcap Ledger Black Diamond Therapeutics, Inc. $BDTX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Cambridge, MA
- Fiscal year end
- December 31
- Shares outstanding
- 57,453,747 [10-Q 2026-08-05]
What the company doesAI summary of filing
Black Diamond Therapeutics is a clinical-stage oncology company developing small molecule inhibitors called MasterKey therapies designed to target families of oncogenic mutations in patients with cancer. The company's lead program, silevertinib, is a brain-penetrant EGFR inhibitor currently in Phase 2 clinical trials for patients with EGFR mutant non-small cell lung cancer and glioblastoma; the company is preparing to initiate a randomized Phase 2 trial in newly diagnosed glioblastoma patients in the second quarter of 2026. The company is pre-revenue and generates funds through development activities and a license agreement with Servier Pharmaceuticals for one of its programs, BDTX-4933, under which the company received a $70 million upfront payment in March 2025 and is eligible for up to $710 million in milestone payments and royalties. [10-K 2026-03-16]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$18.94M | −$18.20M | $19.19M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | $70.00M | $22.37B | $29.61M | $20.99M | [10-K 2026-03-16] |
| FY ended Dec 2024 | $0.00 | −$69.68B | −$62.30M | $36.44M | [10-K 2026-03-16] |
- Quarterly cash burn
- −$9.10M
- Cash runway Estimate
- ~6.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-31 | 56,585,063 | [10-Q 2024-11-05] |
| 2025-02-28 | 56,662,222 | [10-K 2025-03-06] |
| 2025-05-06 | 56,862,635 | [10-Q 2025-05-12] |
| 2025-08-01 | 56,935,279 | [10-Q 2025-08-07] |
| 2025-10-30 | 56,974,913 | [10-Q 2025-11-06] |
| 2026-03-11 | 57,288,750 | [10-K 2026-03-16] |
| 2026-05-01 | 57,301,774 | [10-Q 2026-05-07] |
| 2026-07-30 | 57,453,747 | [10-Q 2026-08-05] |
- Shelf registration
- S-3 filed 2025-11-13; declared effective 2025-12-03 [S-3 2025-11-13]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-18 | Behbahani Ali | grant | 7,707 | $1.93 | [4 2026-09-21] |
| 2026-09-18 | Raman Prakash | grant | 6,801 | $1.93 | [4 2026-09-21] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations |
| 2026-07-27 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-08 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-29 | 8-K | Shareholder vote results |
| 2026-05-21 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
| 2026-04-29 | DEF 14A | Proxy statement |
| 2026-03-16 | 10-K | Annual report |
| 2026-03-16 | 8-K | Results of operations |
| 2026-02-17 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $BDTX
Email me when Black Diamond Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.